iCAD To Launch Lung, Colon CAD Indications In U.S. By Year-End
This article was originally published in The Gray Sheet
Executive Summary
iCAD, Inc. plans an "aggressive" ClickCAD fee-per-procedure program roll-out in July to low-volume mammography centers
You may also be interested in...
iCAD/Confirma alliance
July launch is planned for iCAD's Second Look 500M computer aided detection (CAD) system, combining film-based mammography review with Confirma's CADstream magnetic resonance imaging (MRI) review technology to aid breast cancer detection, firms announce June 3. The device will cost $219,900, with a per-procedure charge of about $150 for each breast MR/CAD analysis, according to iCAD. CADstream also is available as an upgrade. Separately, iCAD's Second Look200 CAD system gains FDA go-ahead to detect breast cancers, offering up to 94% sensitivity, the firm says. Priced below $70,000, the system is intended for smaller mammography centers that perform less than 15 cases per day, iCAD says. Second Look 200 will be available under iCAD's ClickCAD fee-per-procedure program (1"The Gray Sheet" May 10, 2004, p. 27)...
iCAD/Confirma alliance
July launch is planned for iCAD's Second Look 500M computer aided detection (CAD) system, combining film-based mammography review with Confirma's CADstream magnetic resonance imaging (MRI) review technology to aid breast cancer detection, firms announce June 3. The device will cost $219,900, with a per-procedure charge of about $150 for each breast MR/CAD analysis, according to iCAD. CADstream also is available as an upgrade. Separately, iCAD's Second Look200 CAD system gains FDA go-ahead to detect breast cancers, offering up to 94% sensitivity, the firm says. Priced below $70,000, the system is intended for smaller mammography centers that perform less than 15 cases per day, iCAD says. Second Look 200 will be available under iCAD's ClickCAD fee-per-procedure program (1"The Gray Sheet" May 10, 2004, p. 27)...
iCAD Takes Aim At R2 Technology With $30 Mil. CADx Acquisition
iCAD will deepen its computer-assisted detection portfolio by developing applications for CADx' Second Look platform to identify cardiovascular disease and lung and colon cancers